Biotech Due Diligence › Metrics › Series A
Key Metrics for Biotech Startups at Series A Stage: Investor Benchmarks
These 4 metrics are what institutional investors evaluate when screening Biotech startups at the Series A stage. Each metric is accompanied by benchmark ranges sourced from our database of 2+ comparable company analyses.
Series A Stage Traction Expectation: $1M ARR target. Demonstrated scalable sales motion with 2+ reps hitting quota. Clear ICP defined.
Metrics Expected at Series A: $500K–$3M ARR, NRR >100%, Gross Margin >65%, CAC Payback <18 months
Metrics Expected at Series A: $500K–$3M ARR, NRR >100%, Gross Margin >65%, CAC Payback <18 months
01. Clinical Stage
IND Filed → Phase I → Phase II → Phase III → FDA Submission
Each stage transition is a major de-risking milestone
Series A context: At Series A stage ($5M–$20M), this metric is the primary evaluation criterion. $1M ARR target. Demonstrated scalable sales motion with 2+ reps hitting quota. Clear ICP defined.
02. Target Patient Population
Rare disease: >200K US patients | Broad indication: millions
Rare disease (orphan) designation offers faster FDA path and market exclusivity
Series A context: At Series A stage ($5M–$20M), this metric is the primary evaluation criterion. $1M ARR target. Demonstrated scalable sales motion with 2+ reps hitting quota. Clear ICP defined.
03. Preclinical Efficacy Data
In vivo (animal) studies with validated disease models
In vitro data alone is insufficient for investment decisions
Series A context: At Series A stage ($5M–$20M), this metric is a secondary signal. $1M ARR target. Demonstrated scalable sales motion with 2+ reps hitting quota. Clear ICP defined.
04. IP Protection
Core composition-of-matter patents with >10 years of exclusivity
Patent expiry timeline determines commercial window
Series A context: At Series A stage ($5M–$20M), this metric is a secondary signal. $1M ARR target. Demonstrated scalable sales motion with 2+ reps hitting quota. Clear ICP defined.
How DDR Benchmarks These Metrics
When you upload a Biotech startup pitch deck, DDR automatically:
- Extracts all Biotech metrics from every slide of the pitch deck
- Benchmarks each metric against 2 comparable Biotech companies
- Flags metrics outside healthy ranges as red flags with severity weighting
- Provides an overall verdict (INVEST / DIG DEEPER / PASS) with score 1–10
- Generates expected return scenarios based on Biotech exit data
Biotech Due Diligence — All Guides
AUTOMATE YOUR BIOTECH DUE DILIGENCE
Screen Any Biotech Startup in 5 Minutes
Upload a pitch deck PDF and DDR automatically runs this full due diligence framework — 13 OSINT sources, founder verification, all sector-specific red flags, comparable company analysis, and INVEST/PASS verdict.
GET YOUR FREE SCAN →